Sign In
26 Sep 2018 13:48
26 September 2018
Â
N4 Pharma Plc
("N4 Pharma" or the "Company")
Â
Grant of options
Â
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company, announces that the Company has today granted a total of 1,004,000 options over ordinary shares in the Company ("Ordinary Shares") to certain members of senior management pursuant to the Company's unapproved share options scheme (the "Options"). The Options have been granted as follows:
Â
| Name | Options over Ordinary Shares previously held | Number of Options granted | Total number of options over Ordinary Shares now held |
| Allen Hey, Head of CMC Program Development, Biologics | 0 | 717,143 | 717,143 |
| Andrew Leishman, Head of Nuvec Development | 0 | 286,857 | 286,857 |
Â
The Options have an exercise price of 6.60p, which was the closing mid-market price of an Ordinary Share in the Company on 25 September 2018, being the day prior to the grant, and can be exercised from three years up until ten years from the date of grant. Following this grant of Options, there are a total of 7,249,084 options outstanding over Ordinary Shares and 11,054,071 warrants outstanding over Ordinary Shares.
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Â
| Â 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Allen William Hey | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Head of CMC Program Development, Biologics, a PDMR | ||||
| b)Â | Initial notification /Amendment | Initial notification | ||||
| 3Â | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800OIN8T68PM7HK77 | ||||
| 4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)  | Description of the financial instrument, type of instrument  Identification code | Ordinary shares of 0.4p each in N4 Pharma PLC   Identification code (ISIN) for N4 Pharma PLC ordinary shares: GB00BYW8QM32 | ||||
| b) | Nature of the transaction | Grant of options | ||||
| c) | Price(s) and volume(s) |
 | ||||
| d) | Aggregated information - Aggregated volume - Price | Â n/a | ||||
| e) | Date of the transaction | 26 September 2018 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
Â
Â
| Â 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Andrew Leishman | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Head of Nuvec Development, a PDMR | ||||
| b)Â | Initial notification /Amendment | Initial notification | ||||
| 3Â | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | N4 Pharma plc | ||||
| b) | LEI | 213800OIN8T68PM7HK77 | ||||
| 4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)  | Description of the financial instrument, type of instrument  Identification code | Ordinary shares of 0.4p each in N4 Pharma PLC   Identification code (ISIN) for N4 Pharma PLC ordinary shares: GB00BYW8QM32 | ||||
| b) | Nature of the transaction | Grant of options | ||||
| c) | Price(s) and volume(s) |
 | ||||
| d) | Aggregated information - Aggregated volume - Price | Â n/a | ||||
| e) | Date of the transaction | 26 September 2018 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
Â
Enquiries:
Â
| N4 Pharma Plc Nigel Theobald, CEO | Â Via Alma PR Â |
| Allenby Capital Limited James Reeve/Virginia Bull/Asha Chotai  | Tel: +44(0)203 328 5656 |
| Alma PR Josh Royston Robyn Fisher | Â Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191 |
Â
Â
Follow the stocks
